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Abstract The presence of tumor inﬁltrating T cells has
been shown to be associated with a favorable prognosis
in diﬀerent tumor types. Several strategies have been
developed to identify relevant tumor antigens which can
be used for active immunotherapy strategies. The SE-
REX technique (serological analysis of cDNA expres-
sion libraries) identiﬁes tumor antigens based on a
spontaneous humoral immune response in cancer pa-
tients. This technique is not limited to tumor types that
can be grown in cell culture or depends on established T
cell clones recognizing the autologous tumor. Several
steps of analysis are mandatory to evaluate SEREX-
deﬁned antigens before they become new target antigens
for active immunotherapy: expression analysis; sero-
logical analysis with sera from tumor patients and nor-
mal individuals; identiﬁcation of potential peptide
epitopes for CD8 T cells and evaluation in T cell assays.
This article summarizes our approach of antigen iden-
tiﬁcation and evaluation giving the example of the re-
cently cloned breast cancer antigen NY-BR-1.
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There is growing evidence that the immune system
interacts with tumor cells during the natural course of
the disease. Several investigators have demonstrated for
diﬀerent tumor types that the presence of tumor-inﬁl-
trating lymphocytes is associated with a better prognosis
in individual patients [1, 2, 3, 4]. These clinical obser-
vations suggest that tumor-inﬁltrating lymphocytes rec-
ognize speciﬁc antigens expressed by the tumor.
Moreover, this immune response is somehow eﬀective
because it results in a better prognosis and prolonged
survival of the individual patient. Several strategies have
been developed to identify tumor antigens recognized by
T cells: The T-cell epitope cloning technique developed
by T. Boon’s group [5] was successful in identifying tu-
mor antigens based on their recognition by cytotoxic
T cells (CTLs). The ﬁrst cloned antigen by this technique
was the melanoma antigen MAGE-1. Subsequently, new
tumor antigens like those in the BAGE and GAGE gene
family were identiﬁed following this cloning strategy [6,
7]. These antigens share some characteristic features:
their expression in normal tissues is restricted to germ
cells in the testis and the ovary, whereas these antigens
are widely expressed in tumor tissues. Therefore, this
group of antigens was recognized as a separate category,
named ‘‘cancer-testis’’ antigens [8, 9]. A diﬀerent cate-
gory of antigens comprises the diﬀerentiation antigens
which are expressed in normal cells and tissues like
melanocytes and their malignant counterpart, the mel-
anoma. By using the same T-cell epitope cloning tech-
nique, Melan-A [10], tyrosinase [11], gp100 [12], and
gp75 [13] were identiﬁed as T-cell–deﬁned tumor anti-
gens. Tumor-speciﬁc mutated antigens (CDK4, p53) can
also be targets for cytotoxic T cells [14, 15]. Mutated
antigens represent individual antigens; the mutation is
typically not shared by other individuals, with a few
exceptions like the k-ras oncogene mutated in pancreatic
cancer. Viral antigens are frequently expressed in certain
cancers like cervical carcinoma and can be recognized by
T lymphocytes [16].
A diﬀerent antigen-discovery strategy analyzes pep-
tide sequences which were eluted from MHC I com-
plexes isolated from tumor cell lysates. By comparing
the peptide sequence to databases, the relevant tumor
antigen can be identiﬁed [17].
The identiﬁcation of tumor antigens that elicited
spontaneous T-cell responses in cancer patients and
the discovery of the mechanisms of antigen expression,
processing, and MHC class I–restricted presentation of
antigen-derived peptides made it possible to design
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peptide-based immunotherapy protocols. Patients with
antigen-positive tumors were vaccinated with the rel-
evant peptides that are naturally processed and pre-
sented in the context of the respective MHC I
molecule [18]. It was shown in several phase I/II
clinical studies that antigen-speciﬁc cellular immune
responses (CD4 and CD8) can be induced by immu-
nizing patients with the respective peptide [19, 20, 21,
22, 23, 24, 25]. In some patients, objective clinical
remissions of single metastases and long-term clinical
stabilizations were observed, whereas progression of
antigen-negative lesions was frequently documented.
This tumor escape phenomenon under antigen-speciﬁc
immunotherapy reﬂects the development of clonal
heterogeneity over time in most solid tumors. To cir-
cumvent the selection of antigen-negative tumor cell
clones that have a proliferation advantage under the
selection pressure of antigen-speciﬁc immunotherapy,
polyvalent immunotherapy approaches targeting an
array of tumor antigens at the same time are devel-
oped. To design such polyvalent immunotherapy
strategies, it will be necessary to dissect the antigen
expression proﬁle of a given tumor.
The development of a new cloning technique called
SEREX (serological expression cloning) [26] to identify
tumor antigens, based on a spontaneous humoral im-
mune response in the cancer patient, made it possible to
analyze tumor systems independent of the need to grow
them in cell culture. Furthermore, the SEREX technique
does not rely on T cell lines that recognize the autolo-
gous tumor [27]. It was shown for the SEREX-deﬁned
antigen NY-ESO-1 that spontaneous CD8 T-cell re-
sponses correlate to a high percentage with a humoral
immune response in patients with NY-ESO-1–positive
tumors. Dissecting the humoral immune response
against tumor antigens deﬁnes the CD4 T-cell antigen
repertoire of an individual patient. These antigens can
potentially be recognized by CD8 T cells [21, 28]. The
SEREX technique was applied to diﬀerent tumor types
which led to the identiﬁcation of HOM-MEL-40, a gene
identical to the synovial sarcoma/X breakpoint 2 gene
(SSX2) involved in the t(x:18) translocation in synovial
sarcoma [29], as well as other cancer-testis (CT) antigens
including NY-ESO-1 [30], CT7/MAGE-C1 [31], SCP-1
[32], OY-TES-1 [34], HOM-TES-85 [35], CAGE [36],
cTAGE [33], and recently NY-SAR-35 [37]. Besides the
new CT antigens, we were successful with the SEREX
technique in identifying several new diﬀerentiation
antigens like Rab38 [38] and NY-BR-1 [39], as well as
overexpressed antigens like tumor protein D52, NY-BR-
62 or NY-BR-85. SEREX represents a useful screening
technique to deﬁne the individual CD4 T-cell tumor-
antigen repertoire. Today, more than 1,000 antigens
have been identiﬁed by SEREX and deposited in the
SEREX database of the Ludwig Institute for Cancer
Research (http://www.licr.org/SEREX.html).
Several steps of analysis are required before it is
established that SEREX-deﬁned antigens become
potential target antigens for active immunotherapy trials
in cancer patients:
In the ﬁrst step, a careful expression analysis for each
antigen has to be performed by comparing the cDNA
sequence to EST databases. Antigens with restricted
expression by database analysis are being tested by RT-
PCR using a panel of normal tissue and tumor tissue
cDNAs to conﬁrm the restricted mRNA expression
pattern.
Antigens that show a tumor/tissue-restricted
expression pattern undergo a serological analysis to
deﬁne the frequency of humoral immune responses in
sera derived from cancer patients and normal indi-
viduals. A limited number of sera can be tested using
the phage-plaque assay; for large-scale serology, the
recombinant protein has to be produced and tested in
Western blot assays.
Antigens with tumor/tissue-speciﬁc expression and
detectable humoral immune responses in tumor patients
are analyzed for T-cell recognition. We follow an ap-
proach called the ‘‘reverse immunology approach’’
where we test the entire protein sequence of the respec-
tive antigen for potential MHC class I–binding se-
quences (see CancerImmunomeDB, SYFPEITHI
database of MHC ligands and peptide motifs at http://
www.bmi-heidelberg.com/syfpeithi/). We focus primar-
ily on HLA-A2 epitopes because HLA-A2 represents the
most frequent MHC class I allele in the Western Euro-
pean population. Peptide-speciﬁc CTLs can be gener-
ated upon in vitro stimulation, and recognition of target
cells expressing the antigenic protein will be docu-
mented. Finally, CD8 T-cell reactivity to the identiﬁed
epitope can be analyzed in peripheral blood and tumor
lesions of a large series of HLA-A2–positive patients
with antigen-positive tumors.
Tumor antigens that fall in the categories of CT
antigens or diﬀerentiation antigens which represent
target antigens for CD8 T cells can be used to immunize
HLA-A2–positive patients with antigen-positive tumors.
The petides that are recognized by CD8 T cells will be
used for intradermal injection. The readout includes
DTH reaction, induction of peptide-speciﬁc CD8 T cells
(ELISPOT, Multimer), and clinical evolution of the
disease. The following list summarizes the steps of
analyzing SEREX-deﬁned antigens as potential targets
for CD8 T cells:
– SEREX analysis
#
– Database analysis
#
– Expression analysis
#
145
– Serology
#
– MHC-motif search for epitopes
#
– ELISPOT assays (T-cell reactivity)
#
– Immunotherapy trial
These diﬀerent steps of analysis are illustrated in a
recent SEREX analysis performed by our group. In an
autologous SEREX screening of a breast cancer cDNA
expression library we identiﬁed a previously unknown
antigen designated as NY-BR-1. About half of the
clones identiﬁed in the screening were derived from NY-
BR-1, while the other clones were derived from distinct
known and unknown genes. Comparison with EST da-
tabases showed only some cDNA sequences matching
the NY-BR-1 cDNA. Interestingly, some sequences were
derived from testis, one sequence was derived from
normal breast. All other antigens identiﬁed in this
screening matched to cDNA sequences derived from a
wide array of normal tissues and were not further ana-
lyzed.
Following a combined approach of RACE-PCR and
database analysis for overlapping cDNA sequences to
complete the 5‘-cDNA sequence, we were able to clone
the full length NY-BR-1 cDNA which is approximately
6 kb, coding for a protein of approximately 160 kDA.
RT-PCR analysis in a normal tissue panel using NY-
BR-1–speciﬁc primers showed NY-BR-1 mRNA to be
exclusively expressed in normal breast and normal testis,
and variable in normal prostate. In tumor tisues, NY-
BR-1 is expressed in 70–80% of breast cancers, 25% of
prostate cancers, while all other tumor types are NY-
BR-1–negative [39].
Based on the expression analysis, NY-BR-1 repre-
sents a new member of the group of diﬀerentiation
antigens. We produced a short carboxyl-terminal re-
combinant protein for larger scale serological analysis
and found humoral immune responses in approxi-
mately 10% of patients with NY-BR-1–positive breast
cancers. Importantly, all normal sera were tested
negative. To further elucidate T-cell responses against
NY-BR-1, the entire NY-BR-1 protein sequence was
screened for potential HLA-A2–binding motifs. In-
deed, numerous potentially binding peptides were
synthesized. CD8 T cells derived from PBMCs of the
seropositive HLA-A2–positive breast cancer patient
were stimulated once with each of the peptides and
then tested in an ELISPOT assay for speciﬁc recog-
nition. We could identify some peptides that were
speciﬁcally recognized by CD8 T cells. We could
further demonstrate that those peptides represent
naturally processed and presented NY-BR-1 epitopes
(D. Ja¨ger et al., unpublished data).
In summary, we (1) discovered a new tumor antigen
by applying the SEREX technology, (2) demonstrated a
tumor-speciﬁc expression pattern, and (3) identiﬁed
NY-BR-1–derived peptide epitopes that are naturally
processed and presented to CD8 T cells. A phase I
clinical trial for HLA-A2–positive patients with ad-
vanced NY-BR-1–expressing breast cancer or prostate
cancer is under way. Vaccination with the two NY-BR-
1–derived peptides will show if potent antigen-speciﬁc
CD8 T-cell responses can be induced. Clinical eﬀects
and potential side eﬀects in normal breast tissue will be
carefully analyzed.
As illustrated with this example, but demonstrated
previously for other antigens such as NY-ESO-1, the
identiﬁcation of new tumor antigens by SEREX tech-
nology is essential to broaden the spectrum of target
antigens, a prerequisite for making future cancer vac-
cines more eﬃcient.
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